Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medical Research Methodology
Published in: BMC Medical Research Methodology 1/2002

Open Access 01-12-2002 | Debate

The probability of cost-effectiveness

Authors: Anthony O'Hagan, John W Stevens

Published in: BMC Medical Research Methodology | Issue 1/2002

Login to get access

Abstract

Background

The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinctions.

Discussion

We discuss alternative measures in the framework of individual, patient-level, incremental net benefits. In particular we examine the probability of cost-effectiveness for an individual, proposed by Willan.

Summary

We argue that this is a useful addition to the range of cost-effectiveness measures, but will be of secondary interest to most decision makers. We also demonstrate that Willan's proposed estimate of this probability is logically flawed.
Appendix
Available only for authorised users
Literature
1.
2.
Thompson SG, Barber JA: How should cost data in pragmatic randomised trials be analysed?. British Medical Journal. 2000, 320: 1197-1200. 10.1136/bmj.320.7243.1197.CrossRefPubMedPubMedCentral
3.
Stinnett AA, Mullahy J: Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998, 18: S65-S80.CrossRef
4.
Briggs AH, Mooney CZ, Wonderling DE: Constructing confidence intervals for cost-effectiveness ratios: An evaluation of parametric and non-parametric techniques using monte carlo simulation. Statistics in Medicine. 1999, 18: 3245-3262. 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2.CrossRefPubMed
5.
Briggs AH, Wonderling DE, Mooney CZ: Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Economics. 1997, 6: 327-340. 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W.CrossRefPubMed
6.
Chaudhary MA, Steams SC: Estimating confidence intervals for cost-effectiveness ratios: An example from a randomised trial. Statistics in Medicine. 1996, 15: 1447-1458. 10.1002/(SICI)1097-0258(19960715)15:13<1447::AID-SIM267>3.0.CO;2-V.CrossRefPubMed
7.
Laska EM, Meisner M, Siegel C: Statistical inference for cost-effectiveness ratios. Health Economics. 1997, 6: 229-242. 10.1002/(SICI)1099-1050(199705)6:3<229::AID-HEC268>3.0.CO;2-M.CrossRefPubMed
8.
O'Brien BJ, Drummond MF, Labelle RJ, Willan AR: In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Medical Care. 1994, 32: 150-163.CrossRefPubMed
9.
Polsky D, Glick HA, Wilike R, Schulman K: Confidence intervals for cost-effectiveness ratio: A comparison of four methods. Health Economics. 1997, 6: 243-252. 10.1002/(SICI)1099-1050(199705)6:3<243::AID-HEC269>3.0.CO;2-Z.CrossRefPubMed
10.
Tambour M, Zethraeus N: Bootstrap confidence intervals for cost-effectiveness ratios: Some simulation results. Health Economics. 1998, 7: 143-147. 10.1002/(SICI)1099-1050(199803)7:2<143::AID-HEC322>3.0.CO;2-Q.CrossRefPubMed
11.
Wakker P, Klaassen MP: Confidence intervals for cost-effectiveness ratios. Health Economics. 1995, 4: 373-381.CrossRefPubMed
12.
Willan AR, O'Brien BJ: Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Economics. 1996, 5: 297-305. 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T.CrossRefPubMed
13.
Tambour M, Zethraeus N, Johannesson M: A note on confidence intervals in cost-effectiveness analysis. International Journal of Technology Assessment in Health Care. 1998, 14: 467-471.CrossRefPubMed
14.
Briggs AH: A Bayesian approach to stochastic cost-effectiveness analysis. Health Economics. 1999, 8: 257-261. 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E.CrossRefPubMed
15.
Heitjan DF, Moskowitz AJ, Whang W: Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Economics. 1999, 8: 191-201. 10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO;2-R.CrossRefPubMed
16.
O'Hagan A, Stevens JW: A framework for cost-effectiveness analysis from clinical trial data. Health Econ. 2001, 10: 302-315. 10.1002/hec.617.CrossRef
17.
O'Hagan A, Stevens JW, Montmartin J: Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. PharmacoEconomics. 2000, 17: 339-349.CrossRefPubMed
18.
Fenwick E, Claxton K, Sculpher M: Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Economics. 2001, 10: 779-787. 10.1002/hec.635.CrossRefPubMed
19.
van Hout BA, Al MJ, Gordon GS, Rutten F: Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994, 3: 309-319.CrossRefPubMed
20.
O'Hagan A, Stevens JW, Montmartin J: Bayesian cost-effectiveness analysis from clinical trial data. Statistics in Medicine. 2001, 20: 733-753. 10.1002/sim.861.CrossRefPubMed
21.
Raikou M, Gray A, Briggs A, Stevens R, Cull C, McGuire A, Fenn P, Stratton I, Holman R, Turner R, on behalf of the UK Prospective Diabetes Study Group: Cost effectiveness analysis of improved blood pressure control with type 2 diabetes: UKPDS 40. BMJ. 1998, 317: 720-726.CrossRef
22.
Sculpher M, Poole L, Cleland J, Drummond M, Armstrong PW, Horowitz JD, Massie BM, Poole-Wilson PA, Ryden L, on behalf of the ATLAS Study Group: Low doses versus high doses of the angiotensin converting enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril And Survival (ATLAS) study. European Journal of Heart Failure. 2000, 2: 447-454. 10.1016/S1388-9842(00)00122-7.CrossRefPubMed
23.
Löthgren M, Zethraeus N: Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics. 2000, 9: 623-630. 10.1002/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V.CrossRefPubMed
Metadata
Title
The probability of cost-effectiveness
Authors
Anthony O'Hagan
John W Stevens
Publication date
01-12-2002
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2002
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-2-5

Other articles of this Issue 1/2002

BMC Medical Research Methodology 1/2002 Go to the issue

Research article

Publication bias in gastroenterological research – a retrospective cohort study based on abstracts submitted to a scientific meeting

Research article

Are the Cochrane group registers comprehensive? A case study of Japanese psychiatry trials

Research article

Threshold protocol for the exchange of confidential medical data

Research article

The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C?

Research article

Markers for early detection of cancer: Statistical guidelines for nested case-control studies

Research article

Bias and heteroscedastic memory error in self-reported health behavior: an investigation using covariance structure analysis